Navigation Links
SeeThruEquity, LLC Initiates Coverage on Pressure BioSciences, Inc.
Date:10/24/2013

SOUTH EASTON, Mass., Oct. 24, 2013 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced that SeeThruEquity, LLC, an independent investment research and corporate access firm, has initiated equity research coverage on the Company. The research report is available for viewing and downloading at www.seethruequity.com.

Any opinions, judgments, estimates, or forecasts regarding the Company's historical or predicted performance or operations made by SeeThruEquity, LLC are theirs alone and do not represent opinions, judgments, estimates, or forecasts of the Company or its management. The Company does not by its reference to the research report prepared by SeeThruEquity, LLC imply its endorsement or adoption of or concurrence with such information, conclusions, or recommendations.

The investment opinions expressed are solely those of SeeThruEquity, LLC. SeeThruEquity, LLC has not been compensated for the preparation of the report on the Company by any third party or the Company.

About SeeThruEquity LLC:

SeeThruEquity, LLC is an investment research and corporate access firm that produces high quality research reports on smallcap and microcap companies with less than $1 billion in market capitalization. The research is unbiased and not paid-for research. These companies have typically been underserved by the traditional Wall Street analyst establishment. We are unfettered by any ties to investment banking or trading, and distribute our high impact research as an approved contributor on Thomson Reuters One (First Call), CapitalIQ, FactSet, Zacks and StockTwits, as well as to our own audience of investors from our corporate website. We also contribute our financial estimates on companies in our research coverage universe to Thomson Estimates (commonly referred to as consensus or consensus estimates on the Street).

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) is focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology ("PCT"). PCT is a patented, enabling technology platform with multiple applications in the estimated $6 billion life sciences sample preparation market. PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. PBI currently focuses its efforts on the development and sale of PCT-enhanced sample preparation systems (instruments and consumables) for mass spectrometry, biomarker discovery, bio-therapeutics characterization, vaccine development, soil and plant biology, forensics, histology, and counter-bioterror applications.

Forward Looking Statements

Statements contained in this press release regarding PBI's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2012, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link:
http://www.pressurebiosciences.com
Please visit us on Facebook, LinkedIn, and Twitter

Investor Contacts:
Richard T. Schumacher, President and CEO (508) 230-1828 (T)
Richard P. Thomley, Acting CFO


'/>"/>
SOURCE Pressure BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
2. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
3. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
4. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
5. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
6. MAQUET Initiates Class I Recall of the FLOW-i Anesthesia System
7. Stryker Initiates Voluntary Product Recall of Modular-Neck Stems
8. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
9. Grifols Initiates Safety Study of Inhaled Alpha1-Proteinase Inhibitor (Human) Following Orphan Drug Designation for Cystic Fibrosis
10. Empire Asset Management Co. Initiates Coverage on Transcept Pharmaceuticals Inc., (NASDAQ: TSPT)
11. Karyopharm Therapeutics Initiates Two Phase 1 Trials with Oral KPT-330, the First Selective Inhibitor of Nuclear Export (SINE), in Patients with Advanced Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... On Thursday, February 16, 2017, ... at the closing bell, while the Dow Jones Industrial ... Moreover, five out of nine sectors ended Thursday,s trading ... sentiment, Stock-Callers.com assessed the following Medical Appliances & Equipment ... SNN ), ABIOMED Inc. (NASDAQ: ABMD ...
(Date:2/16/2017)... 16, 2017 DaVita Inc. (NYSE: DVA ... December 31, 2016. Net income attributable to ... 2016 was $158 million, or $0.80 per share and $880 ... net income attributable to DaVita Inc. for the quarter and ... below, was $192 million, or $0.98 per share, and $789 ...
(Date:2/16/2017)...  Express Scripts (NASDAQ: ESRX ) was recognized today ... within the Health Care: Pharmacy and Other Services category. ... Most Admired Companies," said Tim Wentworth , CEO and President, ... of our 26,000 employees to make medicine more affordable and accessible ... ...
Breaking Medicine Technology:
(Date:2/17/2017)... Rancho Palos Verdes, CA (PRWEB) , ... February ... ... well-being, and emotional flow is Dr. Carol Francis' goals for each ... Federation Retreat Conference, Dr. Carol Francis will demonstrate five different brainwave tools which ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... Conference & Exhibition in Orlando, Fla., February 19-23. Visitors to the company’s booth ... most widely used electronic patient signatures solution in healthcare . , Since ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... clinical operations executives and focusing on all facets of clinical trial planning and ... management , patient engagement, and more. In addition, attendees stopping by Pharmica’s booth ...
(Date:2/17/2017)... Atlanta, GA (PRWEB) , ... February 17, 2017 , ... ... ways to reduce readmissions. Driven in large part by the Hospital Readmission Reduction Program ... has been a key focus area for hospitals across the nation. While many providers ...
(Date:2/17/2017)... ... 17, 2017 , ... Dillon Ruxton Insurance, a Florida-based agency ... in the greater Fort Lauderdale metropolitan region, is embarking on a cooperative food ... years, LifeNet 4 Families has provided a broad range of food provision services ...
Breaking Medicine News(10 mins):